using standard techniques at 24, 48, and 72 hours. A punch biopsy of the site 
will be considered 2 weeks after placement of the skin test. 
2. Serologic responses to the allogeneic determinants and to a panel of HLA-A2 
and HLA-A1 melanoma cell lines not sharing the allogeneic determinants will be 
measured. Samples will be obtained x 3 baseline, then at 7, 14 (prior to the 
second injection), 21, 28 (prior to the third injection), 42, 56, 84, 112, 140 
and 168 days after the first injection, then every scheduled visit in patients 
who remain on study with stable or responding disease. 
3. Safety monitoring - Pre-study : 
Complete history and physical 
PBL for HLA-A, B, C, and HLA-DR typing 
Determination of penicillin/streptomycin allergy by history 
CBC 
CHEM 20 
PT/PTT 
UA 
CxR 
EKG 
HIV/HBsAg 
CT scans of head, chest and abdomen 
Other scans as necessary to follow disease 
IP x 3 to determine immune competence (ie proliferative response to 
mitogens and recall antigens, T cell receptor abnormalities, PBL 
phenotyping) 
All prestudy tests should be performed within 4 weeks of receiving the 
first vaccination. Tests required for tumor measurements should be 
completed no more than 4 weeks prior to the first dose. On day 0 (day of 
first vaccination) a limited interval history and physical and CBC/CHEM 
20 should be obtained. 
4. Safety Monitoring - During Study 
a. On the day of vaccine administration, patients will be observed for 4 hours 
after the injection. Vital signs will be obtained hourly during observation. 
After the first and second injection, the patients will be examined at 24 and 
48 hours with special emphasis on the injection sites and regional lymph 
nodes. An H/P, CBC, chem 20, and U/A will be done weekly for the first four 
weeks, then every other week x 2, then monthly. CxR is obtained at one month. 
[736] 
Recombinant DNA Research, Volume 18 
